Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q1 FY24 Earnings Presentation
21 slides from Themis Medicare's earnings presentation, Aug 17, 2023
Slide 1: Exchange filing cover letter for investor presentation
TML: CS: BSE/NSE CORR: 2023-24 17th August, 2023 Listing Department, Listing Department, BSE Limited, National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, “Exchange Plaza”, Mumbai-400001 Bandra – Kurla Complex, BSE Scrip Code: 530199 Bandra – East, Mumbai- 400 051 NSE Scrip Code: THEMIS
Slide 2: Themis Medicare Ltd. Investor Presentation Q1 FY24
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Investor Presentation Q1 FY24
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 6: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO. said- “The current quarter performance is in line with our strategy to become a leader in hospital business with contribution from this segment slowly inching towards the 40% mark. While this business grew by 11%
Slide 7: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 25 21.6% 23.5% 22.5% 25% 94.4 96.7 91.0 88.8 20 17.2% 20% 80.1 21.7 20.4 21.3 13.1% 15 15% 15.3 10 10% 10.5 5 5% 0 0% Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 PAT (Rs. Cr.) / M
Slide 8: Consolidated Quarterly Financial Highlights – Q1 FY23-24
Consolidated Quarterly Financial Highlights – Q1 FY23-24 Particulars (Rs. Cr.) Q1 FY23-24 Q1 FY22-23 Y-o-Y (%) Q4 FY22-23 Net Revenue 96.65 94.44 2.34% 80.10 Cost of Material Consumed 15.71 18.25 30.32 Purchase of SIT 9.79 7.99 10.58 Changes in Inventory 3.57 3.37 (13.10) Employee Expenses 20.17 16.
Slide 9: Consolidated Annual Financial Highlights
Consolidated Annual Financial Highlights 262.6 Revenue (Rs. Cr.)* Revenue (Rs. Cr.) 394.6 354.3 API Formulation 220.0 230.7 150.3 201.6 136.0 132.0 124.0 80.5 65.6 FY19-20 FY20-21 FY21-22 FY22-23 FY19-20 FY20-21 FY21-22 FY22-23 EBITDA (Rs. Cr.)** / Margin (%) PAT (Rs. Cr.) / Margin (%) 120 30% 24.2%
Slide 10: Balance Sheet Ratios
Balance Sheet Ratios Working Capital Days Debt to Equity* 231 0.67 0.67 219 167 179 0.46 120 0.27 0.27 FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 RoCE** RoE*** 25.34% 25.23% 14.69% 15.88% 16.15% 16.64% 10.93% -1.27% -6.84% 13.50% FY18-19 FY19-20 FY20-21 FY21-22 F
Slide 11: Consolidated Annual Financial Highlights – FY22-23
Consolidated Annual Financial Highlights – FY22-23 Particulars (Rs. Cr.) FY22-23 FY21-22 Y-o-Y (%) Net Revenue 354.32 394.61 (10.21%) Cost of Material Consumed 96.04 113.63 Purchase of SIT 30.12 31.45 Changes in Inventory (7.79) 3.06 Employee Expenses 66.15 51.97 Other Expenses 102.36 98.87 Total Ex
Slide 12: Consolidated Balance Sheet as on 31st Mar'23
Consolidated Balance Sheet as on 31st Mar’23 As on 31st As on 31st As on 31st As on 31st Rs. Cr. Rs. Cr. Mar’23 Mar’22 Mar’23 Mar’22 Shareholders Funds 339.44 287.49 Non Current Assets 249.42 213.62 Share Capital 9.20 9.20 Plant, Property & Equipment 160.97 141.79 Other Equity 330.24 278.29 Capital
Slide 13: Company Overview
S a > S= @ > oe) > E © 2. E ° re)
Slide 14: Snapshot of Company
Snapshot of Company Strategic focus To become Leader in Hospital Business in India with 4 Strong Balance Sheet growing divisions contributing 38% to revenue Total Debt to Equity at 0.27 in FY22-23 3 State of art manufacturing facilities in India – Rs. 1,252 Cr 1 Formulations and 2 APIs (Sythentic +
Slide 15: Strong Business Model
Strong Business Model Businesswise Revenue – Q1 FY23-24 API & Co. Hospital Mkt 38% Hospital Business 47% is major growth 03 driver Trade 01 15% n 02 n Hospital Business API Business Critical Care Division API Legacy Business Businesswise Revenue – FY22-23 Intensive Care New Product Division
Slide 16: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 17: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations Total Manpower 53 12 13.64 R&D 35 (Incl. 2 PhD) 7 (Incl. 1 PhD) 9.51 8.50 Analytical Lab 18 5 Development 5.28 4.59 Groups 5 3 3.43 Product in a year with 5–8 20-24 documentation FY17-18 FY18
Slide 18: Way Ahead
Way Ahead
Slide 19: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business (HB) Segment? Growing market - Themis has strong foot in door through Critical Care Market Highly Fragmented unlike West where 3-4 players control 90% market share Opportunities to grow segments within HB High Entry Barriers Large Product
Slide 20: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business APIs to be developed - in-house New Target Markets consumption and
Slide 21: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Sangameshwar Iyer Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134 Themis Medicare Ltd Adfactors PR Pvt Ltd Email: sangameshwar.iyer@themismedicare.com Email: amit.sharma@adfac